Follow-On Biologics Could Save Medicare $14 Bil. Over 10 Years – PCMA
Executive Summary
Creating a way for FDA to approve follow-on biologics could lead to savings of more than $14 billion for Medicare Part B from fiscal 2007 to 2016, according to a "preliminary assessment" that the Pharmaceutical Care Management Association released Jan. 4
You may also be interested in...
Biogenerics Get A Low Score From CBO, But Is BIO Actually The Loser?
The reaction of stakeholders to the Congressional Budget Office's score of potential savings from follow-on biologics illustrates the challenges for the various players as debate on legislation continues
Biogenerics Get A Low Score From CBO, But Is BIO Actually The Loser?
The reaction of stakeholders to the Congressional Budget Office's score of potential savings from follow-on biologics illustrates the challenges for the various players as debate on legislation continues
High Barriers To Entry For Biogenerics Will Lead To Lower Cost Savings – Duke
Challenges facing potential manufacturers of follow-on biologics such as a higher cost of entry and initially slower uptake will result in lower cost savings than those seen with the launch of small molecule generics, according to Duke University economist Henry Grabowski